Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

19.34B

Market cap19.34B

Price-Earnings ratio

12.62

Price-Earnings ratio12.62

Dividend yield

—

Dividend yield—

Average volume

1.62M

Average volume1.62M

High today

$132.90

High today$132.90

Low today

$124.56

Low today$124.56

Open price

$128.96

Open price$128.96

Volume

2.80M

Volume2.80M

52 Week high

$213.50

52 Week high$213.50

52 Week low

$110.04

52 Week low$110.04

BIIB News

Seeking Alpha 2d

Biogen rises as Alzheimer’s therapy drives Q2 beat

Biogen (NASDAQ:BIIB) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financials for Q2 2025, thanks mainly to a str...

Seeking Alpha 3d

Eisai/Biogen, Eli Lilly highlight long-term data backing Alzheimer’s drugs

Biogen (NASDAQ:BIIB)/Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their respective FDA-approved...

Analyst ratings

51%

of 37 ratings

Buy

45.9%

Hold

51.4%

Sell

2.7%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.